Table 1.

Vaccines administered, autoimmune diagnoses, immunosuppressive regimens and perivaccination management with serial antispike antibody responses

Age/sex	Diagnosis	Immunosuppression	Initial vaccine series	Meds held or modified preinitial Vaccine	Pre-AD1 antibody U/mL*	Additional vaccines	PostAD1 antibody U/mL*	PostAD2 antibody U/mL*	Therapy held periAD†
62F	Myositis	Mycophenolate‡ Prednisone	Pfizer	No	Negative§	AD1: Pfizer AD2: Pfizer	–	<0.4	No
56F	Mucous membrane pemphigoid	Mycophenolate‡	Pfizer	No	<0.4	AD1: J&J AD2: Moderna	<0.8	<0.4	No
67F	Systemic sclerosis	Mycophenolate‡	Pfizer	No	<0.4	AD1: Pfizer AD2: Pfizer	<0.4	2.1	Yes
73M	Myasthenia gravis	Mycophenolate‡ Prednisone	Moderna	No	<0.4	AD1: Pfizer AD2: Pfizer	–	21.8	–
44F	Inflammatory arthritis¶	Abatacept Hydroxychloroquine Methotrexate Prednisone	Pfizer	No	<0.4	AD1:Pfizer AD2: J&J	<0.4	27.1	Yes
55M	Inflammatory arthritis¶	Infliximab Mycophenolate‡	Pfizer	No	Negative§	AD1: Pfizer AD2: Pfizer	<0.8	46.5	Yes
64F	Myositis	Mycophenolate‡	Pfizer	No	Negative§	AD1: Pfizer AD2: Pfizer	38.1	120.9	Yes
53F	Inflammatory arthritis¶	Adalimumab Mycophenolate‡ Prednisone	Pfizer	No	<0.4	AD1: Moderna AD2: Moderna	229	134	No
55M	Sarcoidosis	Infliximab Mycophenolate‡ Prednisone	Pfizer	No	<0.4	AD1: Moderna AD2: Moderna	2.40	1276	Yes
40F	Inflammatory bowel disease	Adalimumab Hydroxychloroquine Methotrexate	Pfizer	No	178.4	AD1: Moderna AD2: Pfizer	601.2	1750	No
49F	Overlap CT disease**	Belimumab Methotrexate Prednisone	Pfizer	No	<0.4	AD1: Pfizer AD2: Pfizer	16.4	>2500
68F	Proliferative nephritis	Mycophenolate‡ Prednisone	Moderna	No	<0.4	AD1: J&J AD2: Moderna	714	>2500	–
53F	Sjὅgren’s syndrome	Azathioprine	J&J	No	<0.4	AD1: Pfizer AD2: Pfizer	>250	>2500	Yes
55F	Minimal change disease	Mycophenolate‡	J&J	No	<0.4	AD1: Moderna AD2: Moderna	>2500	>2500	No
74M	Myositis	Mycophenolate‡	Pfizer	No	Negative§	AD1: Moderna AD2: Moderna	>2500	>2500	Yes
42F	Overlap CT disease**	Hydroxychloroquine Mycophenolate‡	Pfizer	No	<0.4	AD1: Pfizer AD2: Pfizer	–	>2500	Yes
65F	Inflammatory arthritis	Abatacept	J&J	No	Negative§	AD1: Pfizer AD2: Pfizer	–	>2500	Yes
52M	Overlap CT disease**	Hydroxychloroquine Mycophenolate‡	J&J	No	18.6	AD1: Pfizer AD2: Pfizer	>2500	>2500	Yes

- denotes missing data.

^*Roche Elecsys anti-RBD pan-Ig≥0.8 units/mL is considered positive (upper ceiling expanded from>250 to >2500 U/mL per manufacturer).

^†Pre-AD1 median number of doses held for mycophenolate 6, 23 doses of azathioprine held by one patient, and two abatacept infusion held by one patient. Pre-AD2 median number (IQR) of doses of mycophenolate 14 (10–14), 23 doses of azathioprine and 2 abatacept infusion held by one patient.

^‡Mycophenolate includes mycophenolic acid and mycophenolate mofetil.

^§Self-reported values.

^¶Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, or inflammatory bowel disease associated arthritis.

^**Denotes a combination of two or more defined rheumatic diagnoses.

AD, additional dose; J&J, Johnson and Johnson; RBD, receptor binding domain.